174 related articles for article (PubMed ID: 37101403)
1. Model-based approach to identify predictors of paclitaxel-induced myelosuppression in "real-world" administration.
Salem AM; Dvergsten E; Karovic S; Maitland ML; Gopalakrishnan M
CPT Pharmacometrics Syst Pharmacol; 2023 Jul; 12(7):929-940. PubMed ID: 37101403
[TBL] [Abstract][Full Text] [Related]
2. Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring.
Netterberg I; Nielsen EI; Friberg LE; Karlsson MO
Cancer Chemother Pharmacol; 2017 Aug; 80(2):343-353. PubMed ID: 28656382
[TBL] [Abstract][Full Text] [Related]
3. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Hansson EK; Wallin JE; Lindman H; Sandström M; Karlsson MO; Friberg LE
Cancer Chemother Pharmacol; 2010 Apr; 65(5):839-48. PubMed ID: 19680655
[TBL] [Abstract][Full Text] [Related]
4. Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.
Hu L; Lv QL; Guo Y; Cheng L; Wu NY; Qin CZ; Zhou HH
J Clin Pharmacol; 2016 Mar; 56(3):349-54. PubMed ID: 26179145
[TBL] [Abstract][Full Text] [Related]
5. A Pharmacometric Model to Predict Chemotherapy-Induced Myelosuppression and Associated Risk Factors in Non-Small Cell Lung Cancer.
Park K; Kim Y; Son M; Chae D; Park K
Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631500
[TBL] [Abstract][Full Text] [Related]
6. Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony-Stimulating Factor Response Using Model-Based In Vitro to Clinical Translation.
Chen W; Boras B; Sung T; Hu W; Spilker ME; D'Argenio DZ
AAPS J; 2020 Nov; 22(6):143. PubMed ID: 33156437
[TBL] [Abstract][Full Text] [Related]
7. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
Friberg LE; Henningsson A; Maas H; Nguyen L; Karlsson MO
J Clin Oncol; 2002 Dec; 20(24):4713-21. PubMed ID: 12488418
[TBL] [Abstract][Full Text] [Related]
8. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
[TBL] [Abstract][Full Text] [Related]
9. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol.
Carlson JW; Fowler JM; Saltzman AK; Carter JR; Chen MD; Mitchell SK; Dunn D; Carson LF; Adcock LL; Twiggs LB
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):415-20. PubMed ID: 7530677
[TBL] [Abstract][Full Text] [Related]
10. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
Joerger M; Kraff S; Huitema AD; Feiss G; Moritz B; Schellens JH; Beijnen JH; Jaehde U
Clin Pharmacokinet; 2012 Sep; 51(9):607-17. PubMed ID: 22804749
[TBL] [Abstract][Full Text] [Related]
12. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic analysis of combined chemotherapy with carboplatin and paclitaxel for patients with ovarian cancer.
Arakawa A; Nishikawa H; Suzumori K; Kato N
Int J Clin Oncol; 2001 Oct; 6(5):248-52. PubMed ID: 11723747
[TBL] [Abstract][Full Text] [Related]
14. ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients.
Björn N; Jakobsen Falk I; Vergote I; Gréen H
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):277-287. PubMed ID: 29504705
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of patients treated with paclitaxel/carboplatin-based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Gray JR; Morrissey LH; Kalman LA; Hon JK; Greco FA
J Clin Oncol; 2002 Jul; 20(13):2937-42. PubMed ID: 12089222
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.
Tsushima T; Kasai H; Tanigawara Y
Cancer Chemother Pharmacol; 2020 Oct; 86(4):487-495. PubMed ID: 32930844
[TBL] [Abstract][Full Text] [Related]
17. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
Hainsworth JD; Gray JR; Stroup SL; Kalman LA; Patten JE; Hopkins LG; Thomas M; Greco FA
J Clin Oncol; 1997 Dec; 15(12):3464-70. PubMed ID: 9396399
[TBL] [Abstract][Full Text] [Related]
20. A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression.
Kathman SJ; Williams DH; Hodge JP; Dar M
Cancer Chemother Pharmacol; 2009 Feb; 63(3):469-76. PubMed ID: 18443793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
